Nuclear Medicine and Biology
Volume 34, Issue 8 , Pages 945-953 , November 2007

Gallium-68-labeled DOTA-rhenium-cyclized α-melanocyte-stimulating hormone analog for imaging of malignant melanoma

  • Lihui Wei

      Affiliations

    • Mallinckrodt Institute of Radiology, Washington University School of Medicine, St. Louis, MO 63110, USA
    • ,
  • Yubin Miao

      Affiliations

    • Department of Biochemistry, University of Missouri-Columbia, Columbia, MO 65212, USA
    • ,
  • Fabio Gallazzi

      Affiliations

    • Department of Biochemistry, University of Missouri-Columbia, Columbia, MO 65212, USA
    • ,
  • Thomas P. Quinn

      Affiliations

    • Department of Biochemistry, University of Missouri-Columbia, Columbia, MO 65212, USA
    • ,
  • Michael J. Welch

      Affiliations

    • Mallinckrodt Institute of Radiology, Washington University School of Medicine, St. Louis, MO 63110, USA
    • Alvin J. Siteman Cancer Center, Washington University School of Medicine, St. Louis, MO 63110, USA
    • ,
  • Amy L. Vāvere

      Affiliations

    • Mallinckrodt Institute of Radiology, Washington University School of Medicine, St. Louis, MO 63110, USA
    • ,
  • Jason S. Lewis

      Affiliations

    • Mallinckrodt Institute of Radiology, Washington University School of Medicine, St. Louis, MO 63110, USA
    • Alvin J. Siteman Cancer Center, Washington University School of Medicine, St. Louis, MO 63110, USA
    • Corresponding Author InformationCorresponding author. Mallinckrodt Institute of Radiology, Washington University School of Medicine, Campus Box 8225, St. Louis, MO 63110, USA. Tel.: +1 314 362 4696; fax: +1 314 362 9940.

Received 10 April 2007 ,Revised 7 June 2007 ,Accepted 3 July 2007.

References 

  1. Dennis LK. Analysis of the melanoma epidemic, both apparent and real: data from the 1973 through 1994 surveillance, epidemiology, and end results program registry. Arch Dermatol. 1999;135:275–280
  2. Vosmik F. Malignant melanoma of the skin. Epidemiology, risk factors, clinical diagnosis. Csa Lek Cesk. 1996;135:405–408
  3. Eberle AN, Froidevaux S. Radiolabeled alpha-melanocyte-stimulating hormone analogs for receptor-mediated targeting of melanoma: from tritium to indium. J Mol Recognit. 2003;16:248–254
  4. Som P, Atkins HL, Bandoypadhyay D, Fowler JS, MacGregor RR, Matsui K, et al. A fluorinated glucose analog, 2-fluoro-2-deoxy-d-glucose (F-18): nontoxic tracer for rapid tumor detection. J Nucl Med. 1980;21:670–675
  5. Mijnhout GS, Hoekstra OS, van Tulder MW, Teule GJ, Deville WL. Systematic review of the diagnostic accuracy of 18F-fluorodeoxyglucose positron emission tomography in melanoma patients. Cancer. 2001;91:1530–1542
  6. Dimitrakopoulou-Strauss A, Strauss LG, Burger C. Quantitative PET studies in pretreated melanoma patients: a comparison of 6-[18F]fluoro-l-DOPA with 18F-FDG and 15O-water using compartment and noncompartment analysis. J Nucl Med. 2001;42:248–256
  7. Salk D. Technetium-labeled monoclonal antibodies for imaging metastatic melanoma: results of a multicenter clinical study. Semin Oncol. 1988;15:608–618
  8. Taylor A, Milton W, Eyre HP, Christian P, Wu F, Hagan P, et al. Radioimmunodetection of human melanoma with indium-111-labeled monoclonal antibody. J Nucl Med. 1988;29:329–337
  9. Marchitto KS, Kindsvogel WR, Beaumier PL, Fine SK, Gilbert T, Levin SD, et al. Characterization of a human–mouse chimeric antibody reactive with a human melanoma associated antigen. Prog Clin Biol Res. 1989;288:101–105
  10. Adler MJ, White CR. Amelanotic malignant melanoma. Semin Cutan Med Surg. 1997;16:122–130
  11. Eisen TG. The control of gene expression in melanocytes and melanomas. Melanoma Res. 1996;6:277–284
  12. McGovern VJ. Melanoma: histological diagnosis and prognosis. New York: Raven; 1983;
  13. Beer AJ, Haubner R, Goebel M, Luderschmidt S, Spilker ME, Wester HJ, et al. Biodistribution and pharmacokinetics of the alphavbeta3-selective tracer 18F-galacto-RGD in cancer patients. J Nucl Med. 2005;46:1333–1341
  14. Cobben DC, Jager PL, Elsinga PH, Maas B, Suurmeijer AJ, Hoekstra HJ. 3′-18F-Fluoro-3′-deoxy-l-thymidine: a new tracer for staging metastatic melanoma?. J Nucl Med. 2003;44:1927–1932
  15. Kato K, Kubota T, Ikeda M, Tadokoro M, Abe S, Nakano S, et al. Low efficacy of 18F-FDG PET for detection of uveal malignant melanoma compared with 123I-IMP SPECT. J Nucl Med. 2006;47:404–409
  16. Moins N, D'Incan M, Bonafous J, Bacin F, Labarre P, Moreau M, et al. 123I-N-(2-diethylaminoethyl)-2-iodobenzamide: a potential imaging agent for cutaneous melanoma staging. Eur J Nucl Med Mol Imaging. 2002;29:1478–1484
  17. Salopek TG, Scott JR, Joshua AV, Smylie M, Logus JW, Morin CA, et al. Radioiodinated N-[3-(4-morpholino)propyl]-N-methyl-2-hydroxy-5-iodo-3-methylbenzylamine (ERC9): a new potential melanoma imaging agent. Eur J Nucl Med. 2001;28:408–417
  18. Cone RD, Lu D, Koppula S, Vage DI, Klungland H, Boston B, et al. The melanocortin receptors: agonists, antagonists, and the hormonal control of pigmentation. Recent Prog Horm Res. 1996;51:287–317[discussion 318]
  19. Cone RD, Mountjoy KG, Robbins LS, Nadeau JH, Johnson KR, Roselli-Rehfuss L, et al. Cloning and functional characterization of a family of receptors for the melanotropic peptides. Ann N Y Acad Sci. 1993;680:342–363
  20. Eves PC, MacNeil S, Haycock JW. alpha-Melanocyte stimulating hormone, inflammation and human melanoma. Peptides. 2006;27:444–452
  21. Gantz I, Konda Y, Tashiro T, Shimoto Y, Miwa H, Munzert G, et al. Molecular cloning of a novel melanocortin receptor. J Biol Chem. 1993;268:8246–8250
  22. Gantz I, Miwa H, Konda Y, Shimoto Y, Tashiro T, Watson SJ, et al. Molecular cloning, expression, and gene localization of a fourth melanocortin receptor. J Biol Chem. 1993;268:15174–15179
  23. Barrett P, MacDonald A, Helliwell R, Davidson G, Morgan P. Cloning and expression of a new member of the melanocyte-stimulating hormone receptor family. J Mol Endocrinol. 1994;12:203–213
  24. Desarnaud F, Labbe O, Eggerickx D, Vassart G, Parmentier M. Molecular cloning, functional expression and pharmacological characterization of a mouse melanocortin receptor gene. Biochem J. 1994;299:367–373
  25. Labbe O, Desarnaud F, Eggerickx D, Vassart G, Parmentier M. Molecular cloning of a mouse melanocortin 5 receptor gene widely expressed in peripheral tissues. Biochemistry. 1994;33:4543–4549
  26. Eberle AN. In:  Cone RD editors. Propiomelanocortin and the melanocortin peptides. Totowa, New Jersey: Humana Press; 2000;p. 3–67
  27. Tatro JB, Wen Z, Entwistle ML, Atkins MB, Smith TJ, Reichlin S, et al. Interaction of an alpha-melanocyte-stimulating hormone-diphtheria toxin fusion protein with melanotropin receptors in human melanoma metastases. Cancer Res. 1992;52:2545–2548
  28. Tatro JB, Atkins M, Mier JW, Hardarson S, Wolfe H, Smith T, et al. Melanotropin receptors demonstrated in situ in human melanoma. J Clin Invest. 1990;85:1825–1832
  29. Siegrist W, Solca F, Stutz S, Giuffre L, Carrel S, Girard J, et al. Characterization of receptors for alpha-melanocyte-stimulating hormone on human melanoma cells. Cancer Res. 1989;49:6352–6358
  30. Miao Y, Whitener D, Feng W, Owen NK, Chen J, Quinn TP. Evaluation of the human melanoma targeting properties of radiolabeled α-melanocyte stimulating hormone peptide analogues. Bioconjug Chem. 2003;14:1177–1184
  31. Chen J, Giblin MF, Wang N, Jurisson SS, Quinn TP. In vivo evaluation of 99mTc/188Re-labeled linear alpha-melanocyte stimulating hormone analogs for specific melanoma targeting. Nucl Med Biol. 1999;26:687–693
  32. Cheng Z, Xiong Z, Subbarayan M, Chen X, Gambhir SS. 64Cu-labeled alpha-melanocyte-stimulating hormone analog for microPET imaging of melanocortin 1 receptor expression. Bioconjug Chem. 2007;18:765–772
  33. Cheng Z, Zhang L, Graves E, Xiong Z, Dandekar M, Chen X, et al. Small-animal PET of melanocortin 1 receptor expression using a 18F-labeled a-melanocyte-stimulating hormone analog. J Nucl Med. 2007;48:987–994
  34. Froidevaux S, Calame-Christe M, Schuhmacher J, Tanner H, Saffrich R, Henze M, et al. A gallium-labeled DOTA-alpha-melanocyte-stimulating hormone analog for PET imaging of melanoma metastases. J Nucl Med. 2004;45:116–123
  35. Froidevaux S, Calame-Christe M, Sumanovski L, Tanner H, Eberle AN. DOTA a-melanocyte-stimulating hormone analogues for imaging metastatic melanoma lesions. Ann N Y Acad Sci. 2003;994:378–383
  36. Froidevaux S, Calame-Christe M, Tanner H, Eberle AN. Melanoma targeting with DOTA-melanocyte-stimulating hormone analogs: structural parameters affecting tumor uptake and kidney uptake. J Nucl Med. 2005;46:887–895
  37. Froidevaux S, Calame-Christe M, Tanner H, Sumanovski L, Eberle AN. A novel DOTA-alpha-melanocyte-stimulating hormone analog for metastatic melanoma diagnosis. J Nucl Med. 2002;43:1699–1706
  38. Chen J, Cheng Z, Owen NK, Hoffman TJ, Miao Y, Jurisson SS, et al. Evaluation of an 111In-DOTA-rhenium cyclized alpha-MSH analog: a novel cyclic-peptide analog with improved tumor-targeting properties. J Nucl Med. 2001;42:1847–1855
  39. Cheng Z, Chen J, Quinn TP, Jurisson SS. Radioiodination of rhenium cyclized alpha-melanocyte-stimulating hormone resulting in enhanced radioactivity localization and retention in melanoma. Cancer Res. 2004;64:1411–1418
  40. McQuade P, Miao Y, Yoo J, Quinn TP, Welch MJ, Lewis JS. Imaging of melanoma using 64Cu- and 86Y-DOTA-ReCCMSH(Arg11), a cyclized peptide analogue of alpha-MSH. J Med Chem. 2005;48:2985–2992
  41. Blower PJ, Lewis JS, Zweit J. Copper radionuclides and radiopharmaceuticals in nuclear medicine. Nucl Med Biol. 1996;23:957–980
  42. McCarthy DW, Shefer RE, Klinkowstein RE, Bass LA, Margeneau WH, Cutler CS, et al. Efficient production of high specific activity 64Cu using a biomedical cyclotron. Nucl Med Biol. 1997;24:35–43
  43. Yoo J, Tang L, Perkins TA, Rowland DJ, Laforest R, Lewis JS, et al. Preparation of high specific activity 86Y using a small biomedical cyclotron. Nucl Med Biol. 2005;32:891–897
  44. Maecke HR, Hofmann M, Haberkorn U. 68Ga-labeled peptides in tumor imaging. J Nucl Med. 2005;46:172S–178S
  45. Tai YC, Ruangma A, Rowland DJ, Siegel S, Newport DF, Chow PL, et al. Performance evaluation of the microPET Focus: a third-generation microPET scanner dedicated to animal imaging. J Nucl Med. 2005;46:455–463
  46. Wei L, Butcher C, Miao Y, Gallazzi F, Quinn TP, Welch MJ, et al. Synthesis and biological evaluation of Cu-64 labeled rhenium-cyclized a-MSH peptide analog using a cross-bridged cyclam chelator. J Nucl Med. 2007;48:64–72
  47. Sawyer TK, Castrucci AM, Staples DJ, Affholter JA, De Vaux A, Hruby VJ, et al. Structure–activity relationships of [Nle4, d-Phe7]alpha-MSH. Discovery of a tripeptidyl agonist exhibiting sustained bioactivity. Ann N Y Acad Sci. 1993;680:597–599
  48. Sawyer TK, Sanfilippo PJ, Hruby VJ, Engel MH, Heward CB, Burnett JB, et al. 4-Norleucine, 7-d-phenylalanine-alpha-melanocyte-stimulating hormone: a highly potent alpha-melanotropin with ultralong biological activity. Proc Natl Acad Sci U S A. 1980;77:5754–5758
  49. Cody WL, Mahoney M, Knittel JJ, Hruby VJ, Castrucci AM, Hadley ME. Cyclic melanotropins. 9. 7-d-Phenylalanine analogues of the active-site sequence. J Med Chem. 1985;28:583–588
  50. Al-Obeidi F, Castrucci AM, Hadley ME, Hruby VJ. Potent and prolonged acting cyclic lactam analogues of alpha-melanotropin: design based on molecular dynamics. J Med Chem. 1989;32:2555–2561
  51. Hruby VJ, Lu D, Sharma SD, Castrucci AL, Kesterson RA, al-Obeidi FA, et al. Cyclic lactam alpha-melanotropin analogues of Ac-Nle4-cyclo[Asp5, d-Phe7,Lys10] alpha-melanocyte-stimulating hormone-(4–10)-NH2 with bulky aromatic amino acids at position 7 show high antagonist potency and selectivity at specific melanocortin receptors. J Med Chem. 1995;38:3454–3461
  52. Giblin MF, Wang N, Hoffman TJ, Jurisson SS, Quinn TP. Design and characterization of alpha-melanotropin peptide analogs cyclized through rhenium and technetium metal coordination. Proc Natl Acad Sci U S A. 1998;95:12814–12818
  53. Chen J, Cheng Z, Hoffman TJ, Jurisson SS, Quinn TP. Melanoma-targeting properties of (99m)technetium-labeled cyclic alpha-melanocyte-stimulating hormone peptide analogues. Cancer Res. 2000;60:5649–5658
  54. Miao Y, Owen NK, Whitener D, Gallazzi F, Hoffman TJ, Quinn TP. In vivo evaluation of 188Re-labeled alpha-melanocyte stimulating hormone peptide analogs for melanoma therapy. Int J Cancer. 2002;101:480–487
  55. Miao Y, Hofmann M, Quinn TP. Tumor targeting properties of 90Y and 177Lu labeled alpha-melanocyte stimulating hormone peptide analogues in a murine melanoma model. Nucl Med Biol. 2005;32:485–493
  56. Anderson CJ, Dehdashti F, Cutler PD, Schwarz SW, Laforest R, Bass LA, et al. Cu-64-TETA-octreotide as a PET imaging agent for patients with neuroendocrine tumors. J Nucl Med. 2001;42:213–221
  57. Henze M, Schuhmacher J, Hipp P, Kowalski J, Becker DW, Doll J, et al. PET imaging of somatostatin receptors using [68GA]DOTA-d-Phe1-Tyr3-octreotide: first results in patients with meningiomas. J Nucl Med. 2001;42:1053–1056
  58. Jamar F, Barone R, Mathieu I, Walrand S, Labar D, Carlier P, et al. 86Y-DOTA-d-Phe1-Tyr3-octreotide (SMT487)—a phase 1 clinical study: pharmacokinetics, biodistribution and renal protective effect of different regimens of amino acid co-infusion. Eur J Nucl Med Mol Imaging. 2003;30:510–518
  59. Spraugue JE, Peng Y, Sun X, Weisman GR, Wong EH, Achilefu S, et al. Preparation and biological evaluation of copper-64-labeled Tyr3-octreotate using a cross-bridged macrocyclic chelator. Clin Cancer Res. 2004;10:8674–8682
  60. Boswell CA, Sun X, Niu W, Weisman GR, Wong EH, Rheingold AL, et al. Comparative in vivo stability of copper-64-labeled cross-bridged and conventional tetraazamacrocyclic complexes. J Med Chem. 2004;47:1465–1474
  61. Rogers BE, Anderson CJ, Connett JM, Guo LW, Edwards WB, Sherman EL, et al. Comparison of four bifunctional chelates for radiolabeling monoclonal antibodies with copper radioisotopes: biodistribution and metabolism. Bioconjug Chem. 1996;7:511–522
  62. Jones-Wilson TM, Deal KA, Anderson CJ, McCarthy DW, Kovacs Z, Motekaitis RJ, et al. The in vivo behavior of copper-64-labeled azamacrocyclic complexes. Nucl Med Biol. 1998;25:523–530
  63. Heppeler A, Froidevaux S, Mäcke HR, Jermann E, Béhé M, Powell P, et al. Radiometal-labelled macrocyclic chelator-derivatised somatostatin analogue with superb tumour-targeting properties and potential for receptor-mediated internal radiotherapy. Chem Eur J. 1999;5:1974–1981
  64. Breeman WAP, Jong M, Blois E, Bernard BF, Konijnenberg M, Krenning EP. Radiolabelling DOTA-peptides with 68Ga. Eur J Nucl Med Mol Imaging. 2005;32:478–485
  65. Meyer GJ, Maecke H, Schuhmacher J, Knapp WH, Hofmann M. 68Ga-labelled DOTA-derivatised peptide ligands. Eur J Nucl Med Mol Imaging. 2004;31:1097–1104
  66. Bernard BF, Krenning EP, Breeman WAP, Rolleman EJ, Bakker WH, Visser TJ, et al. d-Lysine reduction of indium-111 octreotide and yttrium-90 octreotide renal uptake. J Nucl Med. 1997;38:1929–1933

PII: S0969-8051(07)00183-7

doi: 10.1016/j.nucmedbio.2007.07.003

Nuclear Medicine and Biology
Volume 34, Issue 8 , Pages 945-953 , November 2007

Article Tools

* Image Usage & Resolution